A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers (20130193) First published 07/10/2016 Last updated 01/07/2024 EU PAS number:EUPAS15128 Study Ongoing